# Immunogenicity, Safety of GSKs Tdap Vaccine Boostrix When Coadministered With GSKs Influenza Vaccine Fluarix in Adults

> **NCT00385255** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 1726 (actual)

## Conditions studied

- Acellular Pertussis
- Diphtheria
- Tetanus

## Interventions

- **BIOLOGICAL:** Fluarix®
- **BIOLOGICAL:** Boostrix®

## Key facts

- **NCT ID:** NCT00385255
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-10-23
- **Primary completion:** 2007-02-28
- **Final completion:** 2007-02-28
- **Target enrollment:** 1726 (ACTUAL)
- **Last updated:** 2019-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00385255

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00385255, "Immunogenicity, Safety of GSKs Tdap Vaccine Boostrix When Coadministered With GSKs Influenza Vaccine Fluarix in Adults". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00385255. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*